aspartic acid has been researched along with Head and Neck Neoplasms in 8 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 8.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 4.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sansa, A | 1 |
| Venegas, MDP | 1 |
| Valero, C | 1 |
| Pardo, L | 1 |
| Avilés-Jurado, FX | 1 |
| Terra, X | 1 |
| Quer, M | 1 |
| León, X | 1 |
| Naz, S | 1 |
| Leiker, AJ | 1 |
| Choudhuri, R | 1 |
| Preston, O | 1 |
| Sowers, AL | 1 |
| Gohain, S | 1 |
| Gamson, J | 1 |
| Mathias, A | 1 |
| Van Waes, C | 1 |
| Cook, JA | 1 |
| Mitchell, JB | 1 |
| Peters, GJ | 1 |
| Bertero, T | 1 |
| Oldham, WM | 1 |
| Grasset, EM | 1 |
| Bourget, I | 1 |
| Boulter, E | 1 |
| Pisano, S | 1 |
| Hofman, P | 1 |
| Bellvert, F | 1 |
| Meneguzzi, G | 1 |
| Bulavin, DV | 1 |
| Estrach, S | 1 |
| Feral, CC | 1 |
| Chan, SY | 1 |
| Bozec, A | 1 |
| Gaggioli, C | 1 |
| Quintela-Fandino, M | 1 |
| Hitt, R | 1 |
| Medina, PP | 1 |
| Gamarra, S | 1 |
| Manso, L | 1 |
| Cortes-Funes, H | 1 |
| Sanchez-Cespedes, M | 1 |
| Langer, CJ | 1 |
| Schaebler, D | 1 |
| Sauter, E | 1 |
| DeMaria, D | 1 |
| Johnson, C | 1 |
| Reilly, DM | 1 |
| Clark, J | 1 |
| Leighton, J | 1 |
| Aks, C | 1 |
| Litwin, S | 1 |
| Ridge, JA | 1 |
| Vokes, EE | 1 |
| Mick, R | 1 |
| Vogelzang, NJ | 1 |
| Geiser, R | 1 |
| Douglas, F | 1 |
| Kemeny, N | 1 |
| Schneider, A | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
2 trials available for aspartic acid and Head and Neck Neoplasms
| Article | Year |
|---|---|
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.
Topics: Aspartic Acid; Cisplatin; Head and Neck Neoplasms; Humans; Magnesium | 1990 |
6 other studies available for aspartic acid and Head and Neck Neoplasms
| Article | Year |
|---|---|
The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers, Tumor; Carcin | 2021 |
Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Topics: Animals; Aspartic Acid; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Co | 2021 |
Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Topics: Amides; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Biphenyl Compounds; Ca | 2018 |
Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aspartic Acid; Breast Neoplasms; Cancer-Associated Fi | 2019 |
DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Combined Chemotherapy Protocols; Arginine; A | 2006 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |